Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MITF | O75030 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675594 | 1.00 | NLRP3 (0.62) | NLRP3ALDH1A1MAPK1MITFHTT | |
| SCHEMBL11802189 | 0.88 | ALDH1A1 (0.67) | ALDH1A1MAPK1MITFHTTPOLB | |
| SCHEMBL5142374 | 0.86 | ALDH1A1 (0.66) | NLRP3ALDH1A1MAPK1CYP1A2MEN1 | |
| SCHEMBL4188909 | 0.86 | NLRP3 (0.59) | NLRP3ALDH1A1MAPK1POLBCYP1A2 | |
| SCHEMBL29720309 | 0.86 | NLRP3 (0.59) | NLRP3ALDH1A1MAPK1POLBCYP1A2 | |
| SCHEMBL9799670 | 0.83 | ALDH1A1 (0.61) | NLRP3ALDH1A1MAPK1CYP1A2MEN1 | |
| SCHEMBL127182 | 0.81 | CA1 (0.61) | NLRP3ALDH1A1MAPK1CYP1A2MEN1 | |
| SCHEMBL441932 | 0.81 | HDAC4 (0.67) | NLRP3ALDH1A1POLBCYP1A2MEN1 | |
| SCHEMBL14202768 | 0.81 | ALDH1A1 (0.59) | NLRP3ALDH1A1POLBCYP1A2MEN1 | |
| SCHEMBL6360996 | 0.81 | RAB9A (0.69) | NLRP3ALDH1A1MAPK1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912436-A | A kind of synthetic method of oxadiazon intermediate | 安徽省化工研究院 | 2019-06-21 | — | — | CN | claimed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| CN-111615388-B | Immunotherapeutic agent for cancer | 斯汀格瑞治疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| EP-3658138-B1 | SUBSTITUTED-3H-IMIDAZO(4,5-C)PYRIDINE AND 1H-PYRROLO(2,3-C)PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHSPHATASE/PHOSPHODIESTRASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATOR AS CANCER IMMUNOTHERAPEUTICS | STINGRAY THERAPEUTICS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| CN-112996496-A | substituted-3H-imidazo [4,5-c ] pyridines and 1H-pyrrolo [2,3-c ] pyridines as novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and interferon gene Stimulator (STING) modulators for cancer immunotherapy | 斯汀格瑞治疗股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3829561-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-4473374-A | Nitrated coupler compounds useful in direct dyeing and simultaneous oxidation and direct dyeing of keratinic fibers | SOCIETE ANONYME DITE: L'OREAL (FR) | 1984-09-25 | — | — | US | disclosed |
| US-4330291-A | Nitrated coupler compounds useful in direct dyeing and simultaneous oxidation and direct dyeing of keratinic fibers | SOCIETE ANONYME DITE: L'OREAL (FR) | 1982-05-18 | — | — | US | disclosed |
| US-4248591-A | HAIR DYES | L'OREAL (FR) | 1981-02-03 | — | — | US | disclosed |
| US-4221729-A | HAIR DYES | L'OREAL (FR) | 1980-09-09 | — | — | US | disclosed |
| US-4093806-A | HAIR DYES | L'OREAL (FR) | 1978-06-06 | — | — | US | disclosed |
| US-4046786-A | HAIR DYES | L'OREAL (FR) | 1977-09-06 | — | — | US | disclosed |
| US-3977825-A | Indoanilines in keratinic fiber dye cmpositions | L'OREAL (FR) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337677-A1 | ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF | DDT, ACHE, AHR | NLRP3 829/4885ALDH1A1 2254/4885MAPK1 4248/4885 |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | NLRP3 1259/4885ALDH1A1 3527/4885MAPK1 1001/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | NLRP3 4734/4885ALDH1A1 3714/4885MAPK1 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.